Symbols

SMTI

Sanara·NASDAQ

--(--)

SMTI fundamentals

SMTI Q4 2025 Earnings

Sanara (SMTI) released its earnings on Mar 24, 2026: revenue was 27.55M (YoY +4.72%), beat estimates; EPS was -0.19 (YoY -5.56%), missed estimates.

Revenue / YoY

27.55M

+4.72%

EPS / YoY

-0.19

-5.56%

Report date

Mar 24, 2026

SMTI Earnings Call Summary for Q4,2025

Revenue record: 2025 net revenue surpasses $100M for first time at $103.1M (+19% YoY).
Margin strength: Gross margin expands to 93%, with $17M adjusted EBITDA and $6.8M cash from operations.
Distributor expansion: 450+ distributors and 1,450+ healthcare facilities served, driving surgical market penetration.
2026 growth: Guided for $116-121M net revenue (+13-17%), fueled by BIASURGE/Vizient deal and CellerateRX clinical/economic validation.

Earnings

EPS

Revenue

Revenue & Expenses

SMTI has released its 2025 Q4 earnings report, with revenue of 27.55M, reflecting a YoY change of 4.72%, and net profit of -1.61M, showing a YoY change of 5.32%. The Sankey diagram below clearly presents SMTI's revenue sources and cost distribution.

Key Indicators

Sanara (SMTI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Sanara (SMTI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Sanara (SMTI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Sanara (SMTI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown